- Home
- SLN vs HERE Comparison
SLN vs HERE Comparison
Compare SLN & HERE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLN | HERE |
|---|---|---|
| Founded | 1994 | 2019 |
| Country | United Kingdom | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 318.4M | 296.4M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | SLN | HERE |
|---|---|---|
| Price | $6.57 | $5.13 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $39.67 | N/A |
| AVG Volume (30 Days) | 314.1K | ★ 353.4K |
| Earning Date | 11-06-2025 | 12-02-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.17 |
| EPS | N/A | ★ 1.45 |
| Revenue | $25,830,000.00 | ★ $286,877,037.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $14.46 |
| P/E Ratio | ★ N/A | $7.96 |
| Revenue Growth | ★ 40.39 | N/A |
| 52 Week Low | $1.97 | $1.60 |
| 52 Week High | $8.08 | $15.64 |
Technical Indicators
Market Signals| Indicator | SLN | HERE |
|---|---|---|
| Relative Strength Index (RSI) | 50.57 | N/A |
| Support Level | $5.95 | N/A |
| Resistance Level | $6.60 | N/A |
| Average True Range (ATR) | 0.53 | 0.00 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 41.33 | 0.00 |
Price Performance
Historical ComparisonAbout SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.